Chockalingam "Palani" Palaniappan, Ph.D., Chief Technology Officer, Epic Sciences
Epic Sciences has named Chockalingam "Palani" Palaniappan as its new chief technology officer (CTO) to help the company advance its Functional Cell Profiling technology to drive global expansion. In his new role, Dr. Palaniappan will lead the vision for building a globally deployable, regulated platform for routine use of clinical applications for a range of cancer indications, as well as enabling drug discovery in biopharmaceutical industries. This new addition adds another life science veteran from global diagnostics and clinical drug development industries to the company's executive management team.
"Dr. Palaniappan's extensive experience leading technology teams and driving transformative innovations across multinational corporations will be an invaluable asset as we expand our menu of oncology solutions in the U.S. and international markets," said Lloyd Sanders, president and CEO at Epic Sciences. "We're just beginning to tap the power of our technology to transform cancer care by providing the clarity to guide treatment decisions to extend patient lives."
Dr. Palaniappan has more than 20 years of experience across diverse life sciences fields serving academia, pharmaceutical, biotechnology, clinical labs, hospitals and blood centers around the world. He has helped steer wide ranging disruptive innovation from molecular, cellular to direct patient connected platforms.
"The incredible power of Epic's unique liquid biopsy technology to non-invasively diagnose, treat and extend cancer patients' lives is a powerful enabler of precision medicine," said Dr. Palaniappan.
Before joining Epic, Dr. Palaniappan was the executive vice president of Innovation and Development and a board member of the Terumo Global Blood Management at Terumo BCT, a global leader in blood management, therapeutic apheresis, cell therapy and regenerative medicine. Prior to this role, he served as the vice president for Research and Development for Cellular Analysis at Life Technologies. Preceding that, he was the head of Molecular Diagnostics for the Amersham Life Sciences unit of GE Healthcare. Dr. Palaniappan has a Ph.D. in the field of biological sciences from Northern Illinois University, followed by a post-doctoral fellowship at the University of Rochester in HIV biology.